WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced the approval of a new compensation agreement. The company's Compensation Committee, consisting entirely of independent directors, has approved the grant of non-qualified stock options for the purchase of 175,000 shares of Viridian's common stock to a new employee. This Inducement Grant, dated July 1, 2025, is issued outside of the company's 2016 Equity Incentive Plan but adheres to its terms. The grant has an exercise price matching Viridian's stock closing price on the grant date and will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the next three years.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.